Step 1
Decompose
Turn the pitch into the claims that must be true for the deal to work. Rank them by decision importance. Drop anything that does not change the check.
Decision Sprint method
How we test the science case for one live deal.
You get a map with sources of what must be true: what holds against published evidence, what conflicts, and what we could not establish. Tempus is a major precision-medicine company that uses biomedical data and knowledge graphs to test drug-development hypotheses for industry. BioticaBio does that job for investors—claim testing against the evidence graph, then a human write-up for your partners. This is not certainty, not a standing diligence bench, and not a substitute for specialist counsel.
Four steps
Step 2
Check the evidence
Test each material claim against published literature, trials, targets, labels, patents, and known failure modes. Look for support and contradiction.
Step 3
Integrate
Connect technical findings to timeline, capital need, and financing consequences. Write what the science means for the investment call.
Step 4
Decide
State what holds, what conflicts, and what evidence would change the view. Deliver a brief, memo, and partner briefing with sources attached.
What the evidence graph adds
- Published literature and trial precedents for the modality and indication
- Target, mechanism, and competitive-class context
- Regulatory labels and public failure modes that bear on the thesis
- Patent and prior-art signals for diligence context—not legal advice
How findings are written
- Support: evidence that strengthens the claim, with limits noted.
- Contradiction: conflicting evidence or failed analogues, with comparability noted.
- Missing: what we could not establish and why it matters to the call.
- Implication: science, time/capital, questions for management, and the decision trigger.
Inference
We label inference. Material conclusions cite a source, a calculation, or that labeled inference. Gaps stay gaps.
Review
A senior human reviewer owns the investment synthesis. The graph informs the test; it does not write the conclusion. Domains we did not review are listed.
Scope
Work outside the signed scope is unreviewed. A sprint can be fast or deep. It cannot be both.
Why this instead of a full diligence firm
Large firms staff matched specialists for broad transaction coverage. We run a shorter engagement: decompose the thesis, test claims against published evidence, label what is missing, and state what each finding does to the investment call—for one live deal.
Worked patterns live in the decision catalogue.
- Claim map instead of a generic checklist
- Support and contradiction on the page, with sources
- Decision triggers instead of fake probability scores
- Unreviewed domains listed in the memo
What this is not
We do not provide legal opinions, regulatory sign-off, FTO, valuation models, patient-level reanalysis, or investment recommendations. We are not affiliated with Tempus and we are not a clinical real-world evidence platform. We will not sell you a probability-of-success number or a “de-risked” stamp.